Skip to main content
Clinical Trials/NCT04012580
NCT04012580
Completed
N/A

Examining The Acceptability and Effectiveness of Transdiagnostic, Internet-Delivered Cognitive Behaviour Therapy for Symptoms of Postpartum Anxiety and Depression: A Randomized Controlled Trial

University of Regina1 site in 1 country60 target enrollmentSeptember 30, 2019

Overview

Phase
N/A
Intervention
Not specified
Conditions
Depression, Postpartum
Sponsor
University of Regina
Enrollment
60
Locations
1
Primary Endpoint
Change in postpartum depression
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

In the proposed study, the investigators will examine the efficacy of transdiagnostic, Internet-delivered cognitive behaviour therapy (ICBT) in the treatment of postpartum anxiety and depression. Half of participants will receive the treatment immediately, and half of the participants will be assigned to a treatment-as-usual control condition. Participants assigned to the control condition will be offered the treatment after a 12-week waiting period, although data from this portion will not be included in the current study. All participants will complete questionnaires prior to the start of the treatment, following treatment (or corresponding 8-week waiting period), at 1-months follow-up (or corresponding 12-week waiting period), and at 6-months follow-up (in those assigned to the treatment condition). Further, those who receive the treatment will complete questionnaires on a weekly basis. The primary outcome measures include anxiety and depression. As part of the battery of questionnaires administered after the completion of the program, participants will be asked to rate the program content, the overall service, and their satisfaction with the program.

Registry
clinicaltrials.gov
Start Date
September 30, 2019
End Date
November 27, 2020
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • 18 years of age or older
  • have given birth and have a child under one year of age
  • score of 10 or above on EPDS or a score of 9 or above on the GAD-7
  • be a resident of Saskatchewan
  • have access to a secure computer and the Internet, and be comfortable using technology
  • be available to work through treatment each week
  • be willing to provide a medical contact as an emergency contact

Exclusion Criteria

  • younger than 18 years
  • not female
  • have not given birth to a child less than one year of age
  • are experiencing minimal to no symptoms of anxiety and/or depression
  • are not a resident of Saskatchewan
  • have been hospitalized within the last year for mental health and/or suicide risk concerns;
  • have unmanaged problems with alcohol, drugs, psychosis or mania, or are at increased suicide risk (specific plans and intent reflected by the Suicide Behaviors Questionnaire-Revised)
  • started a new psychotropic medication within the past month
  • do not have access to a secure computer and the Internet or is not comfortable using technology
  • are not available to work through treatment each week

Outcomes

Primary Outcomes

Change in postpartum depression

Time Frame: Baseline, weeks 1-9, 13, and 37

Measured by the Edinburgh Postnatal Depression Scale (EPDS). 10 items are summed into a total score ranging from 0 to 30, with higher scores indicating more severe depression.

Change in anxiety

Time Frame: Baseline, weeks 1-9, 13, and 37

Measured by the Generalized Anxiety Disorder Scale 7-Item (GAD-7). 7 items are summed into a total score ranging from 0 to 21, with higher scores indicating more severe self-reported levels of anxiety.

Secondary Outcomes

  • Service utilization(Weeks 9, 13, and 37)
  • Change in depression(Baseline, weeks 1-9, 13, and 37)
  • Change in depression, anxiety, stress(Baseline, 8 weeks, 1 month, and 6 months)
  • Mother-infant bonding(Baseline, weeks 9, 13, and 37)
  • Relationship satisfaction(Baseline, weeks 9, 13, and 37)
  • Treatment credibility(Baseline and week 9)
  • Therapeutic alliance(9 weeks following baseline)
  • Treatment satisfaction(9 weeks following baseline)
  • Adverse effects(9 weeks following baseline)

Study Sites (1)

Loading locations...

Similar Trials